Nwam LLC Has $2.47 Million Stock Position in Danaher Co. (NYSE:DHR)

Nwam LLC trimmed its position in Danaher Co. (NYSE:DHR) by 18.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 10,746 shares of the conglomerate’s stock after selling 2,423 shares during the quarter. Nwam LLC’s holdings in Danaher were worth $2,467,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of DHR. Heck Capital Advisors LLC bought a new position in Danaher during the fourth quarter worth $27,000. Decker Retirement Planning Inc. bought a new position in Danaher during the fourth quarter worth $31,000. Golden State Wealth Management LLC bought a new position in Danaher during the fourth quarter worth $31,000. Strategic Financial Concepts LLC bought a new position in Danaher during the fourth quarter worth $31,000. Finally, Pineridge Advisors LLC increased its position in Danaher by 63.3% during the fourth quarter. Pineridge Advisors LLC now owns 147 shares of the conglomerate’s stock worth $34,000 after acquiring an additional 57 shares during the period. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Stock Down 1.8 %

Shares of NYSE DHR opened at $205.69 on Friday. The firm’s 50-day simple moving average is $225.00 and its 200 day simple moving average is $245.50. The company has a market cap of $147.01 billion, a price-to-earnings ratio of 38.96, a price-to-earnings-growth ratio of 2.66 and a beta of 0.83. The company has a quick ratio of 1.05, a current ratio of 1.40 and a debt-to-equity ratio of 0.31. Danaher Co. has a 12-month low of $196.80 and a 12-month high of $281.70.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, hitting the consensus estimate of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same quarter in the prior year, the business posted $2.09 EPS. On average, research analysts expect that Danaher Co. will post 7.63 earnings per share for the current fiscal year.

Danaher Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be given a dividend of $0.32 per share. The ex-dividend date is Friday, March 28th. This is an increase from Danaher’s previous quarterly dividend of $0.27. This represents a $1.28 dividend on an annualized basis and a yield of 0.62%. Danaher’s dividend payout ratio is presently 24.24%.

Insider Buying and Selling at Danaher

In other Danaher news, SVP Brian W. Ellis sold 5,700 shares of the company’s stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the transaction, the senior vice president now directly owns 20,230 shares in the company, valued at approximately $4,534,149.90. This represents a 21.98 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 11.10% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. Barclays dropped their target price on shares of Danaher from $275.00 to $240.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 30th. Scotiabank began coverage on shares of Danaher in a research report on Monday, December 23rd. They set a “sector perform” rating and a $265.00 target price on the stock. JPMorgan Chase & Co. lowered their price target on shares of Danaher from $310.00 to $300.00 and set an “overweight” rating on the stock in a report on Tuesday, January 28th. Raymond James reissued a “market perform” rating on shares of Danaher in a report on Monday, February 3rd. Finally, Wolfe Research raised shares of Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price target on the stock in a report on Thursday, October 31st. Seven analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $278.00.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.